Despite advances in understanding the contribution of mTOR hyperactivation to the pathogenesis of TSC and FCD IIb and initial clinical trials of mTOR inhibitors in TSC 8, 9, 10, more specific pathogenic alterations that could be targeted by pharmacotherapy remain to be identified. This evidence concerns the gene TSC1 and fleck corneal dystrophy.